OraLiva is pleased to announce a collaboration with Rovers Medical Devices, a global leader in medical sampling devices, to support the OraLiva’s AI-powered oral cytology test.
As part of the collaboration, OraLiva will utilize Rovers’ Orcellex® brush technology, which is designed to collect high-quality transepithelial cellular samples. These samples are then analyzed using OraLiva’s advanced cytology platform and artificial intelligence models to help identify cellular abnormalities associated with oral cancer and precancerous lesions.
High-quality cellular sampling is a critical component of cytology-based diagnostics. By integrating Rovers’ proven collection technology with OraLiva’s AI-driven analytical platform, the collaboration aims to support earlier detection of oral cancer in routine dental settings.
Oral cancer continues to present a significant public health challenge, with many cases diagnosed at late stages when treatment becomes more complex and outcomes worsen. OraLiva’s platform is designed to enable dental providers to perform simple, non-invasive cytology sampling during routine examinations, helping identify patients who may require further evaluation.
The collaboration reflects a shared commitment to advancing innovative diagnostic tools that can be integrated into everyday clinical workflows and improve patient outcomes through earlier detection.
More information about the announcement from Rovers Medical Devices can be found in their press release: Rovers Medical Devices Expands Clinical Applications of the Orcellex Brush Through Collaboration with OraLiva’s New AI-powered Oral Cancer Screening Test
